Claude Nicaise - 29 Jan 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Reporting relationship: Director
Issuer ticker: SRPT
Reported as of: 29 Jan 2026
Net transaction value: +$15.6
SEC form: 4
Accepted by SEC: 29 Jan 2026, 20:05:03 UTC
Prior SEC filing: 25 Jun 2025
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise

Key filing fact

Claude Nicaise filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 29 Jan 2026.

Key facts

This page summarizes Claude Nicaise's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jan 2026, 20:05.

Change

Previous filing in this sequence was filed on 25 Jun 2025.
Current net transaction value: +$15.6.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644162 Primary reporting owner

Nicaise Claude

Relationship: Director
Address: 215 FIRST STREET, SUITE 415, CAMBRIDGE
Signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise
Signature date: 29 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRPT transaction

Common Stock

Options Exercise

Transaction value: $143,955
Shares: +10,500
Change %: +38%
Price: $13.71
Shares after: 38,312
Date: 29 Jan 2026
Ownership: Direct

SRPT transaction

Common Stock

Tax liability

Transaction value: $143,939
Shares: -6,780
Change %: -18%
Price: $21.23
Shares after: 31,532
Date: 29 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRPT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -10,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 29 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,500
Exercise price: $13.71

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not wittheld by the Issuer.